Zobrazeno 1 - 10
of 50
pro vyhledávání: '"William K. Murphy"'
Autor:
Waun Ki Hong, Jin S. Lee, J. L. Palmer, Bonnie S. Glisson, Roman Perez-Soler, William K. Murphy, Frank V. Fossella, Dong M. Shin
Publikováno v:
Cancer. 82:301-308
BACKGROUND The combination of cisplatin, ifosfamide, and prolonged oral etoposide (PIE) was studied in patients with extensive small cell lung carcinoma (SCLC) in a Phase I trial followed by a Phase II trial to determine the maximum tolerated dose (M
Autor:
Jonathan M. Kurie, Saroj Vadhan-Raj, Jin Soo Lee, Dong M. Shin, William K. Murphy, Randi A. Schea, Bonnie S. Glisson, Roman Perez-Soler, Frank V. Fossella, Ritsuko Komaki
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 40:331-336
Purpose: Recent studies document the value of early combined modality therapy of small cell lung cancer, but also indicate that early thoracic radiation adds to myelosuppression and can complicate further chemotherapy. Other studies indicate that sim
Autor:
Scott M. Lippman, Jin Soo Lee, Roman Perez-Soler, M. Calayag-Jung, Dong M. Shin, P. Tarassoff, Frank V. Fossella, Bonnie S. Glisson, Edgardo Rivera, William K. Murphy, Waun Ki Hong
Publikováno v:
Journal of Clinical Oncology. 15:310-316
PURPOSE We conducted a phase I trial of the novel nucleoside analog, gemcitabine, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) to determine the maximum-tolerated dose and efficacy in this population. PATIENT AND MET
Autor:
Waun Ki Hong, R A Robinson, Bonnie L. Kemp, J. Jack Lee, Dong M. Shin, Martin N. Raber, Roman Perez-Soler, Jangsoon Lee, J Kane, Frank V. Fossella, William K. Murphy, Scott M. Lippman, Jonathan M. Kurie, Martin H. Huber, Bonnie S. Glisson
Publikováno v:
Journal of Clinical Oncology. 14:503-513
PURPOSE This study was designed to assess the anti-tumor activity of topotecan (TPT) in patients with advanced non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy. PATIENTS AND METHODS Patients with stage IIIB or IV NSCLC with m
Autor:
William K. Murphy, Theera Umsawasdi, Marion J. McMurtrey, Dong M. Shin, Marvin H. Chasen, Ritsuko Komaki, Garret Walsh, Frank V. Fossella, Waun Ki Hong
Publikováno v:
Cancer. 76:2230-2236
Background. This study was designed to determine the efficacy and side effects of a combination of cyclophosphamide (C), doxorubicin (D), and cisplatin (P) in patients with inoperable, unresectable, or metastatic malignant pleural mesothelioma. Metho
Autor:
D. M. Shin, Frank V. Fossella, William K. Murphy, R Perez-Soler, Jin Soo Lee, Bonnie S. Glisson, M Huber, M Calayag, S Benner, Scott M. Lippman
Publikováno v:
Journal of Clinical Oncology. 13:645-651
PURPOSE We conducted a phase II study to determine the response to and toxicity of docetaxel (Taxotere; Rhône-Poulenc Rorer Pharmaceuticals, Inc, Collegeville, PA) in patients with advanced non-small-cell lung cancer refractory to prior platinum-con
Autor:
William K. Murphy, S Benner, A Pang, Bonnie S. Glisson, M Calayag, Frank V. Fossella, M Chasen, Jin Soo Lee, D. M. Shin, Scott M. Lippman
Publikováno v:
Journal of Clinical Oncology. 12:1238-1244
PURPOSE We conducted a phase II study to determine the response and toxicity of docetaxel (Taxotere; Rhône-Poulenc Rorer Pharmaceuticals, Inc, Collegeville, PA) in chemotherapy-naive patients with advanced non-small-cell lung cancer. PATIENTS AND ME
Autor:
Joseph Leimert, Rodger J. Winn, Dong M. Shin, Howard M. Gross, Hari M. Dhingra, H. E. Hynes, Martin N. Raber, Frank V. Fossella, William K. Murphy, Waun Ki Hong, Enrique Davilla, Irwin H. Krakoff
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:384-388
Background Taxol, a complex plant product (a diterpene) extracted from the bark of Taxus brevifolia, has demonstrated substantial anticancer activity in ovarian and breast cancers, malignant melanoma, and acute myelogenous leukemia. Due to allergic r
Autor:
Montague Lane, Steven M. Grunberg, Eric P. Lester, Kasi S. Sridhar, Polly E. Sanderson, Joanne E. Mortimer, William K. Murphy
Publikováno v:
Cancer Chemotherapy and Pharmacology. 32:268-272
The selective 5-hydroxytryptamine3 (5HT3) antagonist ondansetron has been shown to be an effective antiemetic in patients receiving cisplatin chemotherapy. This double-blind study compared the efficacy and safety of three doses of intravenous ondanse
Publikováno v:
American Journal of Clinical Oncology. 15:194-199
Forty-six patients with metastatic non-small-cell lung cancer (NSCLC) were treated with a combination of high-dose cisplatin, etoposide, and mitomycin. Thirty-four patients (74%) had a performance status of 1, and 39 patients (85%) had adenocarcinoma